Shenzhen Immunofoco Biotechnology Co., Ltd.

深圳易慕峰生物科技股份有限公司

Develops CAR-T cell therapies for solid tumors, with lead candidates IMC002 (anti-CLDN18.2, second-most clinically advanced globally per the prospectus) and IMC001 (anti-EpCAM), plus an in vivo CAR-T platform, serving cancer patients in China and worldwide.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Supplier concentration
• Outsourced production (OEM / contract manufacturing)
• Capacity and utilisation
• Losses and path to profitability
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Investments and fair-value assets
• Chapter 18A biotech